Rejuvenation Technologies
Tuesday, June 04, 2024
Regenerative Medicine
Company Presentation Theater 3
Rejuvenation Technologies is extending telomeres using telomerase RNA to treat age-related diseases. Our pipeline includes respiratory, hepatic, and hematopoietic deficiency indications. We recently received over $5M in grants including a $4M grant from the California Institute of Regenerative Medicine (CIRM) to extend telomeres to treat pulmonary fibrosis. Since being launched from Stanford University the founders have developed highly efficient and well-tolerated delivery vehicles for delivering mRNA and circular RNA to extra-hepatic targets. We are on track to begin clinical trials in 2025.
.png)
Company Website:
http://rejuvenationtech.com
Lead Product in Development:
RNA/LNP biologics to extend telomeres to treat pulmonary fibrosis, liver disease, hematopoietic deficiency respectively
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Company HQ City
Mountain View
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
John Ramunas
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())